Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities

Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P. Singh, Salomon Amar

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

There are substantial shortcomings in the drugs currently available for treatment of type 2 diabetes mellitus. The global diabetic crisis has not abated despite the introduction of new types of drugs and targets. Persistent unaddressed patient needs remain a significant factor in the quest for new leads in routine studies. Drug discovery methods in this area have followed developments in the market, contributing to a recent rise in the number of molecules. Nevertheless, troubling developments and fresh challenges are still evident. Recently, metformin, the most widely used first-line drug for diabetes, was found to contain a carcinogenic contaminant known as N-nitroso dimethylamine (NDMA). Therefore, purity and toxicity are also a big challenge for drug discovery and development. Moreover, newer drug classes against SGLT-2 illustrate both progress and difficulties. The same was true previously in the case of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Furthermore, researchers must study the importance of mechanistic characteristics of novel compounds, as well as exposure-related hazardous aspects of current and newly identified protein targets, in order to identify new pharmacological molecules with improved selectivity and specificity.

Original languageEnglish
Article number331
JournalBiomedicines
Volume10
Issue number2
DOIs
Publication statusPublished - 31-01-2022

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities'. Together they form a unique fingerprint.

Cite this